Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Data from an 8-month extension of a 4-month double-blind, placebo-controlled Phase II trial showed Ostabolin-C met the primary
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury